CureVac (CVAC) Expected to Announce Quarterly Earnings on Thursday

CureVac (NASDAQ:CVAC - Get Free Report) is projected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 22nd. Analysts expect the company to announce earnings of ($0.16) per share and revenue of $4.27 million for the quarter.

CureVac (NASDAQ:CVAC - Get Free Report) last released its earnings results on Thursday, April 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.01). The company had revenue of $15.44 million during the quarter, compared to analysts' expectations of $6.40 million. CureVac had a net margin of 20.72% and a return on equity of 21.98%. On average, analysts expect CureVac to post $1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CureVac Stock Up 8.8%

NASDAQ:CVAC traded up $0.30 during midday trading on Friday, reaching $3.72. The company had a trading volume of 907,740 shares, compared to its average volume of 794,023. The firm has a market capitalization of $834.54 million, a price-to-earnings ratio of 6.76 and a beta of 2.43. The stock's fifty day simple moving average is $3.14 and its 200-day simple moving average is $3.24. CureVac has a 12-month low of $2.37 and a 12-month high of $5.28. The company has a current ratio of 6.20, a quick ratio of 6.19 and a debt-to-equity ratio of 0.05.

Institutional Trading of CureVac

A number of hedge funds and other institutional investors have recently bought and sold shares of CVAC. Integrated Wealth Concepts LLC raised its stake in CureVac by 25.0% in the first quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company's stock valued at $42,000 after buying an additional 3,000 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in CureVac in the first quarter valued at $142,000. Finally, Millennium Management LLC raised its stake in CureVac by 10.3% in the first quarter. Millennium Management LLC now owns 1,816,984 shares of the company's stock valued at $5,033,000 after buying an additional 169,947 shares in the last quarter. 17.26% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

CVAC has been the subject of a number of recent research reports. UBS Group decreased their target price on CureVac from $13.00 to $12.00 and set a "buy" rating for the company in a report on Wednesday, April 30th. JMP Securities restated a "market outperform" rating and issued a $16.00 price target on shares of CureVac in a research note on Friday, February 14th.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.